Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)

被引：3
|
作者：
Hellmann, M. D. [1 ]
Rizvi, N. [1 ]
Gettinger, S. N. [2 ]
Goldman, J. [3 ]
Chow, L. Q. [4 ]
Juergens, R. [5 ]
Borghaei, H. [6 ]
Brahmer, J. [7 ]
Shen, Y. [8 ]
Harbison, C. T. [9 ]
Nathan, F. [10 ]
Ready, N. E. [11 ]
Antonia, S. J. [12 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, Div Solid Tumor Oncol, New York, NY 10021 USA
[2] Yale Comprehens Canc Ctr, Med Oncol, New Haven, CT USA
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Hematol Oncol, Los Angeles, CA 90024 USA
[4] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA
[5] Juravinski Canc Ctr, Dept Oncol, Hamilton, ON, Canada
[6] Fox Chase Canc Ctr, Med Oncol, Philadelphia, PA 19111 USA
[7] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Div Oncol, Baltimore, MD USA
[8] Bristol Myers Squibb Co, Biostat, Princeton, NJ USA
[9] Bristol Myers Squibb Co, Immunosci Metab Dis & Fibrosis, Princeton, NJ USA
[10] Bristol Myers Squibb Co, Clin Res, Princeton, NJ USA
[11] Duke Univ, Med Ctr, Div Oncol, Durham, NC USA
[12] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Dept, Tampa, FL 33612 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31738-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3097
引用
收藏
页码：S632 / S633
页数：2
相关论文
共 50 条
  • [1] First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses
    Gettinger, S. N.
    Hellmann, M. D.
    Shepherd, F. A.
    Antonia, S. J.
    Brahmer, J.
    Chow, L. Q.
    Goldman, J.
    Juergens, R.
    Borghaei, H.
    Ready, N. E.
    Gerber, D. E.
    Nathan, F.
    Shen, Y.
    Harbison, C. T.
    Rizvi, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S632 - S632
  • [2] Safety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)
    Rizvi, Naiyer A.
    Gettinger, Scott N.
    Goldman, Jonathan W.
    Hellmann, Matthew D.
    Chow, Laura Q.
    Juergens, Rosalyn
    Borghaei, Hossein
    Brahmer, Julie R.
    Shen, Yun
    Harbison, Christopher
    Nathan, Faith
    Ready, Neal
    Antonia, Scott J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S176 - S176
  • [3] TUMOR GROWTH DYNAMIC (TGD) MODELING AND SAFETY ANALYSIS OF NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) IN FIRST-LINE (1L) PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC).
    Zhao, X.
    Feng, Y.
    Wang, X.
    Young, T. C.
    Maier, S.
    Bello, A.
    Roy, A.
    Agrawal, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S53 - S53
  • [4] Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.
    Gainor, Justin F.
    Schneider, Jeffrey Gary
    Gutierrez, Martin
    Orcutt, James Michael
    Finley, Gene Grant
    Otterson, Gregory Alan
    Rybkin, Igor I.
    Reddy, Pavan S.
    Horn, Leora
    Brahmer, Julie R.
    Bastos, Bruno R.
    Awad, Mark M.
    Hellmann, Matthew David
    Ramalingam, Suresh S.
    Ready, Neal E.
    Spigel, David R.
    Kasinathan, Ravi S.
    Dorange, Cecile
    Borghaei, Hossein
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in Asian patients (pts) with advanced non-small cell lung cancer (aNSCLC) in CheckMate 227
    O'Byrne, K. J.
    Lee, K. H.
    Kim, S-W.
    Park, K.
    Nishio, M.
    Sakai, H.
    Ohe, Y.
    Fukuhara, T.
    Kang, J-H.
    Daga, H.
    Yu, C-J.
    Hotta, K.
    Tanaka, H.
    Takeda, M.
    Yokoyama, T.
    Nathan, F. E.
    Lee, J-S.
    ANNALS OF ONCOLOGY, 2020, 31 : S824 - S824
  • [6] First-line nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC): Results from an interim analysis of the non-interventional FINN study
    Kuon, J. B.
    von der Heyde, E.
    Wilop, S.
    Behringer, D. M.
    Blau, W.
    Huebner, G.
    Flieger, D.
    Forstbauer, H.
    Groschek, M.
    Laack, H-E.
    Mueller-Huesmann, H.
    Schumann, C.
    Waldenberger, D.
    Guetz, S.
    ANNALS OF ONCOLOGY, 2023, 34
  • [7] CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC
    Hellmann, Matthew David
    Gettinger, Scott N.
    Goldman, Jonathan Wade
    Brahmer, Julie R.
    Borghaei, Hossein
    Chow, Laura Q.
    Ready, Neal
    Gerber, David E.
    Juergens, Rosalyn A.
    Shepherd, Frances A.
    Laurie, Scott Andrew
    Zhou, Ye
    Geese, William J.
    Agrawal, Shruti
    Li, Xuemei
    Antonia, Scott Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
    Satoshi Endo
    Hisao Imai
    Atsuto Mouri
    Kasumi Tsukamoto
    Kenji Masaki
    Kosuke Hashimoto
    Yu Miura
    Ayako Shiono
    Ou Yamaguchi
    Junichi Nakagawa
    Kyoichi Kaira
    Kunihiko Kobayashi
    Hiroshi Kagamu
    Journal of Cancer Research and Clinical Oncology, 151 (1)
  • [9] Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)
    Antonia, S. J.
    Gettinger, S.
    Goldman, J.
    Chow, L. Q.
    Juergens, R.
    Borghaei, H.
    Brahmer, J. R.
    Shen, Y.
    Harbison, C.
    Chen, A. C.
    Ready, N. E.
    Rizvi, N. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S32 - S33
  • [10] Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Zhong, R.
    Zhong, H.
    Zhang, B.
    Zhang, W.
    Shi, C.
    Qian, J.
    Han, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S129 - S129
12345